The NEA research team has published its latest paper on the out-of-pocket (OOP) costs of atopic dermatitis (AD) in the U.S. — this time examining OOP costs among caregivers of children with AD compared to adults.
Published On: Mar 18, 2020
Last Updated On: Apr 28, 2021
Released on March 18, 2020, the “More Than Skin Deep” Voice of the Patient Report summarizes outcomes from the September 2019 patient-focused drug development (PFDD) meeting that NEA hosted with four peer patient advocacy organizations. The report radically expands our understanding of the lived experience of patients and caregivers affected by eczema – and will serve as a lasting reference for the regulators, life science companies, researchers and healthcare professionals that NEA partners with to improve the landscape for eczema patients and the people who love them.
For the first time ever, adults and children living with eczema and their family members shared riveting descriptions of symptom burdens, challenges managing the disease and treatment expectations with U.S. Food and Drug Administration (FDA) regulators, drug developers and researchers. This report, submitted to the FDA, shares testimony, data and photos from the in-person participants, virtual attendees and survey respondents (one of the largest surveys of the eczema community to date).
Thank you to the many NEA community members who contributed to the success of the More Than Skin Deep initiative as panel members, audience members, survey respondents or virtual attendees. This enduring report is the result of many brave eczema warriors and caregivers standing tall for the benefit of the greater eczema community, who have been waiting so long for their collective voices to be heard and their experiences understood.
You can watch whole meeting below.